Panama
Tuberculosis profile
| High HIV burden |
Population  2013 3.9 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.18 (0.18–0.19) 4.8 (4.6–4.9)
Mortality (HIV+TB only) 0.042 (0.03–0.056) 1.1 (0.78–1.4)
Prevalence  (includes HIV+TB) 2.4 (1.2–4) 61 (30–103)
Incidence  (includes HIV+TB) 1.8 (1.6–2.1) 48 (42–55)
Incidence (HIV+TB only) 0.24 (0.22–0.28) 6.3 (5.6–7.2)
Case detection, all forms (%) 78 (69–88)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.1) 14 (4.7–22)
MDR-TB cases among notified pulmonary
TB cases
24 (14–34) 24 (9–40)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 719   57
Pulmonary, clinically diagnosed 375   31
Extrapulmonary 247   20
       
Total new and relapse 1 449    
Previously treated, excluding relapses 93    
Total cases notified 1 542    
Among 1 424 new and relapse cases:
113 (8%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 162 (23%) 98 (49%) 295
Laboratory-confirmed RR-/MDR-TB cases     29
Patients started on MDR-TB treatment     4
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 323 (86)
HIV-positive TB patients 175 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 80
Previously treated cases, excluding relapse, registered in 2012 49
HIV-positive TB cases, all types, registered in 2012 63
RR-/MDR-TB cases started on second-line treatment in 2011 29
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 15.5
Drug susceptibility testing (per 5 million population) 1.3
Sites performing Xpert MTB/RIF 6
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 3
% Funded domestically 47%
% Funded internationally 12%
% Unfunded 42%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-28 Data: www.who.int/tb/data